May 4 (Reuters) - K-V Pharmaceutical Co:
* Says recently received report from lachman following re-inspection of the
company's gmp systems
* Says lachman's report includes certification that the company's systems are
in compliance with gmp
* Next step is lachman certification of individual product manufactured in
newly certified gmp systems
* Says working diligently on preparing for manufacture of validation batches of
the first product
* Says manufacture of validation batches of the first product expected to begin
in may
* Says does not anticipate resuming shipment until Q4 of calendar year 2010, at
the earliest
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780))
(For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
* Says recently received report from lachman following re-inspection of the
company's gmp systems
* Says lachman's report includes certification that the company's systems are
in compliance with gmp
* Next step is lachman certification of individual product manufactured in
newly certified gmp systems
* Says working diligently on preparing for manufacture of validation batches of
the first product
* Says manufacture of validation batches of the first product expected to begin
in may
* Says does not anticipate resuming shipment until Q4 of calendar year 2010, at
the earliest
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780))
(For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.